Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

BACKGROUND: For patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), the efficacy and safety of novel P2Y(12) antagonists, including prasugrel or ticagrelor, has not been established relative to that of the clopidogrel-based triple-ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhe, Zhou, Da-Yan, Su, Yong, Si, Liang-Yi, Xu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066764/
https://www.ncbi.nlm.nih.gov/pubmed/32164560
http://dx.doi.org/10.1186/s12872-020-01403-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066764/
https://www.ncbi.nlm.nih.gov/pubmed/32164560
http://dx.doi.org/10.1186/s12872-020-01403-6

Ejemplares similares